Evidence map›Paper›PMID 31991250›Full record

ArticleBone2020

Genetic ablation of SGLT2 function in mice impairs tissue mineral density but does not affect fracture resistance of bone.

Kathryn M Thrailkill, R Clay Bunn, Sasidhar Uppuganti, Philip Ray, Kate Garrett, Iuliana Popescu, Jacquelyn S Pennings, John L Fowlkes, Jeffry S Nyman

Open access · greenAbstract read
In one paragraph

Article in Bone, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Kathryn M ThrailkillUniversity of Kentucky Barnstable Brown Diabetes Center and the Department of Pediatrics, University of Kentucky College of Medicine, Lexington, KY 40536, United States of America. Electronic address: kathryn.thrailkill@uky.edu.
R Clay BunnUniversity of Kentucky Barnstable Brown Diabetes Center and the Department of Pediatrics, University of Kentucky College of Medicine, Lexington, KY 40536, United States of America.
Sasidhar UppugantiDepartment of Orthopaedic Surgery and the Center for Bone Biology, Vanderbilt University Medical Center, Nashville, TN 37232, United States of America; VA Tennessee Valley HealthCare System, Nashville, TN 37217, United States of America.
Philip RayUniversity of Kentucky Barnstable Brown Diabetes Center and the Department of Pediatrics, University of Kentucky College of Medicine, Lexington, KY 40536, United States of America.
Kate GarrettDepartment of Orthopaedic Surgery and the Center for Bone Biology, Vanderbilt University Medical Center, Nashville, TN 37232, United States of America; VA Tennessee Valley HealthCare System, Nashville, TN 37217, United States of America.
Iuliana PopescuUniversity of Kentucky Barnstable Brown Diabetes Center and the Department of Pediatrics, University of Kentucky College of Medicine, Lexington, KY 40536, United States of America.
Jacquelyn S PenningsDepartment of Orthopaedic Surgery and the Center for Musculoskeletal Research, Vanderbilt University Medical Center, Nashville, TN 37232, United States of America.
John L FowlkesUniversity of Kentucky Barnstable Brown Diabetes Center and the Department of Pediatrics, University of Kentucky College of Medicine, Lexington, KY 40536, United States of America.
Jeffry S NymanDepartment of Orthopaedic Surgery and the Center for Bone Biology, Vanderbilt University Medical Center, Nashville, TN 37232, United States of America; VA Tennessee Valley HealthCare System, Nashville, TN 37217, United States of America.
University of Kentucky · USVA Tennessee Valley Healthcare System · USVanderbilt University Medical Center · US

Funding

Effects of Sodium-dependent Glucose Co-transporter 2 Inhibition on Bone.R21AR070620 · NIAMS · UNIVERSITY OF KENTUCKY · PI NYMAN, JEFFRY STEPHEN, THRAILKILL, KATHRYN M · 2016 to 2017
$387k
The insulin/IGF axis in diabetic osteopathyR56DK084045 · NIDDK · UNIVERSITY OF KENTUCKY · PI FOWLKES, JOHN L, NYMAN, JEFFRY STEPHEN · 2018 to 2018
$150k
Aging and Diabetes-Related Factors Compromising Bone Fracture ResistanceI01BX001018 · VA · VETERANS HEALTH ADMINISTRATION · PI NYMAN, JEFFRY STEPHEN · 2011 to 2014
–
Diabetes-Related Changes Affecting Bone QualityI01BX004297 · VA · VETERANS HEALTH ADMINISTRATION · PI NYMAN, JEFFRY STEPHEN · 2019 to 2023
–
BLRD VA I01 BX001018BLRD VA I01 BX004297NIAMS NIH HHS R21 AR070620NIDDK NIH HHS R56 DK084045
6 · The paper itself

Abstract

Selective sodium-dependent glucose co-transporter 2 inhibitors (SGLT2Is) are oral hypoglycemic medications utilized increasingly in the medical management of hyperglycemia among persons with type 2 diabetes (T2D). Despite favorable effects on cardiovascular events, specific SGLT2Is have been associated with an increased risk for atypical fracture and amputation in subgroups of the T2D population, a population that already has a higher risk for typical fragility fractures than the general population. To better understand the effect of SGLT2 blockade on skeletal integrity, independent of diabetes and its co-morbidities, we utilized the "Jimbee" mouse model of slc5a2 gene mutation to investigate the impact of lifelong SGLT2 loss-of-function on metabolic and skeletal phenotype. Jimbee mice maintained normal glucose homeostasis, but exhibited chronic polyuria, glucosuria and hypercalciuria. The Jimbee mutation negatively impacted appendicular growth of the femur and resulted in lower tissue mineral density of both cortical and trabecular bone of the femur mid-shaft and distal femur metaphysis, respectively. Several components of the Jimbee phenotype were characteristic only of male mice compared with female mice, including reductions: in body weight; in cortical area of the mid-shaft; and in trabecular thickness within the metaphysis. Despite these decrements, the strength of femur diaphysis in bending (cortical bone), which increased with age, and the strength of L6 vertebra in compression (primarily trabecular bone), which decreased with age, were not affected by the mutation. Moreover, the age-related decline in bone toughness was less for Jimbee mice, compared with control mice, such that by 49-50 weeks of age, Jimbee mice had significantly tougher femurs in bending than C57BL/6J mice. These results suggest that chronic blockade of SGLT2 in this model reduces the mineralization of bone but does not reduce its fracture resistance.

Indexed as

Diabetes Mellitus, Type 2AnimalsBone DensityFemaleFemurHumansMaleMiceMice, Inbred C57BLMineralsSodium-Glucose Transporter 2MineralsSlc5a2 protein, mouseSodium-Glucose Transporter 2Bone microarchitectureCanagliflozinCortical boneFractureJimbee mouseProximal tubuleTrabecular bone

Identifiers

PMID31991250
PMCPMC7059549
OpenAlexW3002617072

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.